Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

24.96 -0.92 (-3.55%)

Streaming Delayed Price Updated: 10:38 AM EST, Jan 2, 2026 Add to My Watchlist

Price and Volume

Volume	93,103
Open	26.07
Bid (Size)	24.91 (500)
Ask (Size)	25.09 (200)
Prev. Close	25.88
Today's Range	24.90 - 26.81
52wk Range	18.17 - 27.98
Shares Outstanding	44,454,792
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Bridge City Capital Loads Up Onto Innovation Stock With Over 31,000 Shares ↗

December 22, 2025

Post-trade holding: 47,342 shares valued at approximately $6.12 million.

Via The Motley Fool

Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care

December 18, 2025

From Pacira BioSciences

Via GlobeNewswire

Performance

YTD	N/A	N/A
1 Month	+3.7%	+3.7%
3 Month	+1.5%	+1.5%
6 Month	+7.5%	+7.5%
1 Year	+36.2%	+36.2%

More News

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 03, 2025

From Pacira BioSciences

Via GlobeNewswire

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain

December 02, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical

November 26, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

November 11, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

November 06, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

November 05, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

November 04, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

October 30, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee

October 28, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

October 27, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®

October 23, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®

October 21, 2025

From Pacira BioSciences

Via GlobeNewswire

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

October 21, 2025

Via Benzinga

Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy

October 20, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 05, 2025

From Pacira BioSciences

Via GlobeNewswire

PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Emerges as a Strong Value Investing Opportunity ↗

August 13, 2025

Via Chartmill

Pacira (PCRX) Q2 Revenue Rises 1.7% ↗

August 06, 2025

Via The Motley Fool

Pacira BioSciences Inc (NASDAQ:PCRX) Reports Mixed Q2 2025 Earnings with EPS Beat but Revenue Miss ↗

August 05, 2025

Via Chartmill

Pacira BioSciences Reports Second Quarter 2025 Financial Results

August 05, 2025

From Pacira BioSciences

Via GlobeNewswire

Insights Ahead: Pacira BioSciences's Quarterly Earnings ↗

August 04, 2025

Via Benzinga

Frequently Asked Questions

Is Pacira BioSciences, Inc. - Common Stock publicly traded?

Yes, Pacira BioSciences, Inc. - Common Stock is publicly traded.

What exchange does Pacira BioSciences, Inc. - Common Stock trade on?

Pacira BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Pacira BioSciences, Inc. - Common Stock?

The ticker symbol for Pacira BioSciences, Inc. - Common Stock is PCRX on the Nasdaq Stock Market

What is the current price of Pacira BioSciences, Inc. - Common Stock?

The current price of Pacira BioSciences, Inc. - Common Stock is 24.96

When was Pacira BioSciences, Inc. - Common Stock last traded?

The last trade of Pacira BioSciences, Inc. - Common Stock was at 01/02/26 10:38 AM ET

What is the market capitalization of Pacira BioSciences, Inc. - Common Stock?

The market capitalization of Pacira BioSciences, Inc. - Common Stock is 1.11B

How many shares of Pacira BioSciences, Inc. - Common Stock are outstanding?

Pacira BioSciences, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.